Duodenal mucosal resurfacing gains FDA breakthrough device designation for type 2 diabetes ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS You've successfully added to your alerts. You will receive an email when new content is published. Back to Healio We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio The FDA granted breakthrough device designation for a first-in-class duodenal mucosal resurfacing intervention for adults with insulin-treated type 2 diabetes, according to an industry press release.